Taysha Gene Therapies, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
TSHA$4.33+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Condensed Consolidated Statements of Operations
| For the Three MonthsEnded September 30, | For the Nine MonthsEnded September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue | $— | $1,788 | $4,288 | $6,311 |
| Operating expenses: | ||||
| Research and development | 25,745 | 14,946 | 61,451 | 50,676 |
| General and administrative | 8,279 | 7,902 | 25,035 | 22,324 |
| Impairment of long-lived assets | — | 4,838 | — | 4,838 |
| Total operating expenses | 34,024 | 27,686 | 86,486 | 77,838 |
| Loss from operations | (34,024) | (25,898) | (82,198) | (71,527) |
| Other income (expense): | ||||
| Change in fair value of warrant liability | (292) | 75 | (463) | (67) |
| Change in fair value of term loan | (1,534) | (1,703) | (4,525) | (4,035) |
| Interest income | 3,169 | 2,107 | 6,354 | 5,240 |
| Interest expense | (15) | (24) | (51) | (80) |
| Other expense | (37) | (81) | (261) | (44) |
| Total other income, net | 1,291 | 374 | 1,054 | 1,014 |
| Net loss | $(32,733) | $(25,524) | $(81,144) | $(70,513) |
| Net loss per common share, basic and diluted | $(0.09) | $(0.10) | $(0.26) | $(0.29) |
| Weighted average common shares outstanding, basic and diluted | 353,309,524 | 267,824,045 | 307,175,982 | 244,052,057 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.